Post Market Surveillance Programme

The quality of any medicine is determined by its effectiveness, safety and ultimately the health outcome of a patient. If that quality is questionable, then any efforts and investment into public health systems and medicines regulatory systems will be compromised.

The Medicines Quality Control and Surveillance Department functions as a critical part of robust mechanisms for regulating medicines in CARICOM, including post-market surveillance, in close cooperation with the Member States, CARPHA/CRS and other partners such as PAHO/WHO. The laboratory delivers timely, accurate, relevant and authoritative reports on the quality of medicines circulating in CARICOM.

VIgicarib

VigiCarib is a regional system for CMS to report medicines related adverse events (adverse drug/medicine reactions (ADRs/ADMs)) and substandard and falsified products (SF) to bolster states’ ability to conduct the critical regulatory function of monitoring medicines in the market.

learn more ...

post market surveillance programme strategic components

The post market surveillance programme focuses on two strategic components: